These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11290871)

  • 21. Modulation of camptothecin analogs in the treatment of cancer: a review.
    Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
    Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
    Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
    Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vivo imaging in tumor-bearing animals and pharmacokinetics of PEGylated liposomes modified with RGD cyclopeptide].
    Tu LX; Xu YH; Tang CY; Deng LH; Wu CB
    Yao Xue Xue Bao; 2012 May; 47(5):646-51. PubMed ID: 22812011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.
    Schell RF; Sidone BJ; Caron WP; Walsh MD; White TF; Zamboni BA; Ramanathan RK; Zamboni WC
    Nanomedicine; 2014 Jan; 10(1):109-17. PubMed ID: 23891988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
    Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
    Yu NY; Conway C; Pena RL; Chen JY
    Anticancer Res; 2007; 27(4B):2541-5. PubMed ID: 17695551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
    Harasym TO; Cullis PR; Bally MB
    Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
    Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
    Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
    Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].
    Wang CX; Li CL; Zhao X; Yang HY; Wei N; Li YH; Zhang L; Zhang L
    Yao Xue Xue Bao; 2010 Dec; 45(12):1565-9. PubMed ID: 21351498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity and disposition of TLC ELL-12 (liposomal antitumor ether lipid) in Sprague-Dawley rats.
    Bhamra R; Bolcsak LE; Roberts P; Stevens R; Cavanaugh C; Swenson CE
    Anticancer Drugs; 2003 Mar; 14(3):183-91. PubMed ID: 12634612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
    Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L
    Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.
    Zhang LJ; Xing B; Wu J; Xu B; Fang XL
    Pulm Pharmacol Ther; 2008; 21(1):239-46. PubMed ID: 17561423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
    Zamboni WC; Eiseman JL; Strychor S; Rice PM; Joseph E; Zamboni BA; Donnelly MK; Shurer J; Parise RA; Tonda ME; Yu NY; Basse PH
    J Liposome Res; 2011 Mar; 21(1):70-80. PubMed ID: 20528623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.